Paracelsus (c.1493 – 1541), Swiss-German physician and father of modern toxicology
Proterris was co-founded by Apeiron Partners, LLC and a consortium of universities comprised of University of Pittsburgh, Columbia University, Beth Israel Deaconess Medical Center, Johns Hopkins and Yale University. Based on a globally dominant IP position, Proterris is initially focused on therapeutic uses of CO to address significant unmet needs in solid organ transplant.
Carbon monoxide (“CO”) has long been recognized and studied for its therapeutic potential given its unique and potent cytoprotective, anti-inflammatory and anti-fibrotic effects. Indeed, amongst the four therapeutic, so-called “gasotransmitter” gases (CO, nitric oxide, hydrogen sulfide and xenon), CO rivals NO and dwarfs the others in terms of preclinical validation in a wide variety of therapeutic areas. In addition, these therapeutic effects for CO are realized at doses far less than what is already firmly established as toxic levels.
To harness this broad potential, Proterris has amassed a broad array of inhaled & small molecule CO therapeutics for transplant, nephrology, pulmonary and oncology applications, which together address a treatable patient population of more than 20 million patients in the U.S. alone.
